» Articles » PMID: 32902980

Design, Synthesis, and Structure-Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors

Overview
Journal J Med Chem
Specialty Chemistry
Date 2020 Sep 9
PMID 32902980
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The Keap1 (Kelch-like ECH-associated protein 1)-Nrf2 (nuclear factor erythroid 2-related factor 2)-ARE (antioxidant response element) pathway is the major defending mechanism against oxidative stresses, and directly disrupting the Keap1-Nrf2 protein-protein interaction (PPI) has been an attractive strategy to target oxidative stress-related diseases, including cardiovascular diseases. Here, we describe the design, synthesis, and structure-activity relationships (SARs) of indoline-based compounds as potent Keap1-Nrf2 PPI inhibitors. Comprehensive SAR analysis and thermodynamics-guided optimization identified as the most potent inhibitor in this series, with an IC of 22 nM in a competitive fluorescence polarization assay. Further evaluation indicated the proper drug-like properties of . Compound dose-dependently upregulated genes and protein level of Nrf2 as well as its downstream markers and showed protective effects against lipopolysaccharide-induced injury in both H9c2 cardiac cells and mouse models. Collectively, we reported here a novel indoline-based Keap1-Nrf2 PPI inhibitor as a potential cardioprotective agent.

Citing Articles

Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases.

Rojo A, Buttari B, Cadenas S, Carlos A, Cuadrado A, Falcao A Redox Biol. 2024; 79():103464.

PMID: 39709790 PMC: 11733061. DOI: 10.1016/j.redox.2024.103464.


A Review of the Potential of Nuclear Factor [Erythroid-Derived 2]-like 2 Activation in Autoimmune Diseases.

Ates I, Yilmaz A, Buttari B, Arese M, Saso L, Suzen S Brain Sci. 2023; 13(11).

PMID: 38002492 PMC: 10669303. DOI: 10.3390/brainsci13111532.


Modulation of NRF2/KEAP1-Mediated Oxidative Stress for Cancer Treatment by Natural Products Using Pharmacophore-Based Screening, Molecular Docking, and Molecular Dynamics Studies.

Alzain A, Mukhtar R, Abdelmoniem N, Shoaib T, Osman W, Alsulaimany M Molecules. 2023; 28(16).

PMID: 37630254 PMC: 10459127. DOI: 10.3390/molecules28166003.


Design, synthesis and evaluation of novel small molecules acting as Keap1-Nrf2 protein-protein interaction inhibitors.

Sun Y, Zheng L, Yang B, Ge S, Li Q, Zhang M J Enzyme Inhib Med Chem. 2022; 37(1):2575-2588.

PMID: 36128875 PMC: 9518255. DOI: 10.1080/14756366.2022.2124408.


KEAP1-NRF2 protein-protein interaction inhibitors: Design, pharmacological properties and therapeutic potential.

Crisman E, Duarte P, Dauden E, Cuadrado A, Rodriguez-Franco M, Lopez M Med Res Rev. 2022; 43(1):237-287.

PMID: 36086898 PMC: 10087726. DOI: 10.1002/med.21925.